CRISPR THERAPEUTICS
CRISPR Therapeutics AG
Application Filed: 2018-04-11
Trademark Application Details
FINAL REFUSAL - MAILED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87872234 |
| Registration Number | 6055219 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Domestic Representative | Jess M. Collen |
| Attorney Name | Jess M. Collen |
| Attorney Docket Number | Y480 |
| Law Office Assigned | O30 |
| Employee Name | SCHIMPF, TIMOTHY O |
Timeline
| 2013-11-00 | Date of First Use |
| 2018-04-11 | Application Filed |
| 2019-09-27 | Status: Live/Pending |
| 2019-11-25 | Location: TMO LAW OFFICE 130 - SENIOR ATTORNEY |
| 2019-11-25 | Transaction Date |
| 2020-05-12 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  CRISPR Therapeutics AG |
| Entity Statement | aktiengesellschaft |
| Address | Aeschenvorstadt 36 Basel CH 4051 |
| Legal Entity Type | |
| Legal Entity State | CH |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 1 |
| U.S. Codes: | 001,005,006,010,026,046 |
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 41 |
| U.S. Codes: | 100,101,107 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical products and preparations, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders |
| GS0051 | Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical products and preparations, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-04-19 | 1 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2018-07-31 | 2 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2018-08-07 | 3 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2018-08-07 | 4 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2018-08-07 | 5 GNRN O:Outgoing Correspondence |
| TEAS REQUEST TO DIVIDE RECEIVED | 2019-02-07 | 6 ERTD I:Incoming Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-02-07 | 7 TROA I:Incoming Correspondence |
| ASSIGNED TO LIE | 2019-02-12 | 8 ALIE A:Allowance for Publication |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2019-02-13 | 9 AITU A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-02-07 | 10 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-02-21 | 11 TEME I:Incoming Correspondence |
| DIVISIONAL REQUEST RECEIVED | 2019-02-07 | 12 DRRR I:Incoming Correspondence |
| DIVISIONAL PROCESSING COMPLETE | 2019-02-21 | 13 DPCC D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2019-03-13 | 14 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2019-03-13 | 15 GNRT O:Outgoing Correspondence |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2019-03-13 | 16 GNRN O:Outgoing Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2019-04-26 | 17 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2019-04-26 | 18 ARAA I:Incoming Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-09-13 | 19 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-09-17 | 20 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-09-17 | 21 TEME I:Incoming Correspondence |
| FINAL REFUSAL WRITTEN | 2019-09-27 | 22 CNFR R:Renewal |
| FINAL REFUSAL E-MAILED | 2019-09-27 | 23 GNFR O:Outgoing Correspondence |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2019-09-27 | 24 GNFN O:Outgoing Correspondence |
| EXPARTE APPEAL RECEIVED AT TTAB | 2020-03-25 | 25 EXAF T:TTAB Proceeding |
| JURISDICTION RESTORED TO EXAMINING ATTORNEY | 2020-03-25 | 26 JURT T:TTAB Proceeding |
| EX PARTE APPEAL-INSTITUTED | 2020-03-25 | 27 EXPI T:TTAB Proceeding |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2020-03-25 | 28 ERFR I:Incoming Correspondence |
| TEAS AMENDMENT OF USE RECEIVED | 2020-03-25 | 29 EAAU I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2020-03-26 | 30 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2020-03-26 | 31 TEME I:Incoming Correspondence |
| USE AMENDMENT FILED | 2020-03-26 | 32 IUAF S: |
| AMENDMENT TO USE PROCESSING COMPLETE | 2020-03-26 | 33 AUPC I:Incoming Correspondence |
| USE AMENDMENT ACCEPTED | 2020-04-01 | 34 IUAA P: |
| APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | 2020-04-01 | 35 CNTA O:Outgoing Correspondence |
| EXPARTE APPEAL TERMINATED | 2020-04-01 | 36 EXPT T:TTAB Proceeding |
| NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | 2020-04-02 | 37 AAUA E:E-Mail |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2020-04-09 | 38 PREV O:Outgoing Correspondence |
| REGISTERED-SUPPLEMENTAL REGISTER | 2020-05-12 | 39 R.SR A:Allowance for Publication |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2020-08-05 | 40 COAR I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2020-08-05 | 41 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2020-08-05 | 42 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | 2020-08-05 | 43 ECDR I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2020-08-05 | 44 TCCA I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2020-08-05 | 45 CHAN I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2020-08-07 | 46 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2020-08-07 | 47 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | 2020-08-07 | 48 ECDR I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2020-08-07 | 49 TCCA I:Incoming Correspondence |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2021-04-28 | 50 COAR I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2021-04-28 | 51 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2021-04-28 | 52 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2021-04-28 | 53 TCCA I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2021-04-28 | 54 CHAN I:Incoming Correspondence |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 